Organisation paid for research Program year 2025 Source: CMS Open Payments

Sansum Clinic

Neither a doctor nor a teaching hospital

Research payments

$1,187,921

88 payments

Through program year 2025, Sansum Clinic is reported as receiving $1,187,921 in research payments, across 88 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $285,541 2
2024 Research $83,893 5
2023 Research $194,831 4
2022 Research $33,431 9
2021 Research $122,744 44
2020 Research $333,697 15
2019 Research $133,784 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $506,901 7 payments
  2. Amgen Inc. $272,160 9 payments
  3. E.R. Squibb & Sons, L.L.C. $95,598 11 payments
  4. Sanofi Pasteur Inc. $92,115 5 payments
  5. AstraZeneca UK Limited $71,547 2 payments
  6. Medtronic MiniMed, Inc. $57,445 1 payment
  7. Pfizer Inc. $35,070 2 payments
  8. Axonics Modulation Technologies, Inc. $15,254 32 payments
  9. Roche Products Limited $8,975 1 payment
  10. AbbVie, Inc. $7,428 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity Or Overweight (Surpass-T1d-1) $285,452 1 payment
  2. T-VEC + Pembrolizumab in patients progressing on prior anti-PD-1 therapy $270,968 8 payments
  3. A Phase 3 Multicenter Randomized Parallel-Design Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $175,658 2 payments
  4. STA00011 Stamaril Yellow Fever $92,115 5 payments
  5. A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) $71,547 2 payments
  6. CEP 304 670G Outcomes Study $57,445 1 payment
  7. Nivo Dose Frequency Optimization Lung Trial $47,248 3 payments
  8. A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $45,752 3 payments
  9. Polaris Palbociclib in Hormone Receptor Positive Advanced Breast Cancer A Prospective Multicenter Noninterventional Study $35,070 2 payments
  10. SUSTAIN, event driven trial $33,207 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record